RSSDI Repository, Complications of Diabetes Demonstration
RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

Advanced Search
  • Home/
  • Article /
  • Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial

Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial

Add to Collection
RCTs S Gawrieh, M Noureddin, N Loo, R Mohseni… - …, 2021 - Wiley Online Library

Chapter : Section4
Journal Year : 2021
Cited by : 135

… dyslipidemia, peripheral insulin resistance, obesity, type 2 diabetes mellitus (… ( 6, 7 ) It is characterized by insulin resistance and … in India in 2013 for management of diabetic dyslipidemia …..... Read More

Keywords : ['randomized control doubleblind phase trial', 'ppar agonist', 'treatment', 'saroglitazar', 'nafld']
PubMed Link : https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31843
Google Scholar Link : https://scholar.google.com/scholar?cites=5990739075503911783&as_sdt=5,43&sciodt=0,43&hl=en&num=20